Hormone replacement therapy can be an effective treatment for hot flashes, night sweats, vaginal symptoms, and other problems related to declining estrogen during menopause. Understanding the different types of HRT, who may benefit, and how hormone therapy relates to bladder and urinary health can help you make a more informed decision with your healthcare provider.
Updated: August 15, 2026
Author: Dr. Fatima Khan
Hormone replacement therapy (HRT), also called menopausal hormone therapy or simply hormone therapy, is used to replace hormones that decline during the menopause transition. Most HRT contains estrogen, with progesterone or a progestogen added when needed.
HRT is one of the most effective treatments for bothersome menopause symptoms, particularly hot flashes and night sweats. It can also help with vaginal symptoms and help prevent bone loss in appropriate women.
The right treatment depends on your symptoms, whether you still have a uterus, your age and stage of menopause, and your personal and family medical history. HRT is not one standard medication or dose; it can be individualized and delivered in several different ways.
HRT is most commonly used for symptoms related to changing or declining estrogen levels. These may include:
Hormone therapy can also help protect against bone loss and osteoporosis while it is being used. For many healthy women who begin systemic hormone therapy before age 60 or within about 10 years of menopause onset, major menopause organizations consider the benefit-risk balance generally favorable when bothersome symptoms are present.HRT is not intended to treat every symptom that develops in midlife. Weight changes, bladder leakage, fatigue, sleep disorders, thyroid problems, and other conditions may have causes that need to be evaluated separately. If urinary frequency is one of your main concerns, see Causes and Solutions for Frequent Urination.
Hormone therapy can vary both in which hormones are used and how they are delivered.
Estrogen-only therapy may be prescribed to women who have had their uterus removed. Women who still have a uterus generally need a progestogen along with systemic estrogen to help protect the uterine lining.
Systemic estrogen can be delivered through tablets, skin patches, gels, sprays, or other formulations. The route of administration may affect certain risks and side effects, so the best option varies from woman to woman.
Local vaginal estrogen is different from systemic HRT. It uses a low dose of estrogen applied directly to vaginal tissues and is primarily used for genitourinary symptoms such as vaginal dryness, discomfort, and some urinary symptoms. We will discuss that distinction in more detail below.
HRT may be considered when menopause symptoms are bothersome enough to affect quality of life, sleep, work, relationships, or everyday activities.
Age and timing matter. Current guidance generally finds the benefit-risk balance most favorable for healthy women younger than 60 or within 10 years of menopause onset who do not have contraindications to hormone therapy.
Women who experience menopause unusually early may also have different considerations because estrogen plays an important role in bone and other aspects of long-term health before the typical age of natural menopause.
Hormone therapy is a prescription treatment, so the decision should be individualized with a healthcare provider rather than based only on age or the presence of menopause symptoms.
For women with bothersome menopause symptoms, HRT can provide significant relief. Its best-established benefits include reducing hot flashes and night sweats, improving menopause-related sleep disruption, relieving vaginal symptoms, and helping prevent bone loss while treatment continues.
Many women also report improvement in overall quality of life when disruptive menopause symptoms are brought under better control. The degree of benefit depends on the symptoms being treated, the type and dose of hormone therapy, and the individual woman.
HRT may be especially important to discuss in women who experience menopause earlier than expected, because a longer period of low estrogen exposure can affect bone health and other aspects of long-term health.
HRT is not appropriate for everyone, and its risks vary depending on age, medical history, the hormones used, dose, route of administration, and how long treatment is continued.
Potential risks associated with systemic hormone therapy can include blood clots, stroke, gallbladder disease, and certain hormone-sensitive cancers. The absolute level of risk is not the same for every woman, which is why individualized evaluation matters.
Common side effects may include breast tenderness, bloating, headaches, spotting or bleeding, and mood changes, particularly when treatment is first started or adjusted.
Women with a history of certain cancers, unexplained vaginal bleeding, previous blood clots, stroke, heart attack, or significant liver disease may need to avoid systemic HRT or consider alternative treatments. A healthcare provider can help evaluate personal risk factors.
HRT is not limited to women who have already reached menopause. It may also be used during perimenopause when symptoms such as hot flashes, night sweats, or sleep disruption become bothersome.
Because women in perimenopause may still ovulate and become pregnant, HRT should not be considered a form of contraception. Treatment also may need to be adjusted as menstrual patterns and hormone levels continue to change.
If your main concern is new urinary urgency, frequency, or bladder leakage during this stage, see our guide to perimenopause symptoms and bladder problems.
Menopause-related urinary symptoms are more complicated than simply having “low estrogen.” Some women experience urgency, frequency, recurrent urinary tract infections, or vaginal and urinary discomfort as estrogen-sensitive tissues change. Women whose primary symptoms are urgency and frequent urination may also find our guide Overactive Bladder Symptoms: 5 Things to Understand and Conquer helpful.
However, systemic HRT is not considered a primary treatment for urinary incontinence. Stress incontinence, overactive bladder, and mixed incontinence each have their own treatment approaches.For stress urinary incontinence, treatment usually focuses on improving support around the urethra through pelvic floor strengthening or other targeted therapies. Overactive bladder and urgency symptoms involve a different bladder-control pathway and may require bladder- or nerve-directed treatment.
For women with mixed urinary incontinence, Elitone is particularly relevant because it is designed to address both components, combining strengthening-oriented stimulation for stress leakage with calming stimulation for urgency symptoms.
If bladder leakage is your main concern, our guide to menopause and urinary incontinence explains how stress and urge symptoms differ and which treatments may be appropriate.
Systemic HRT circulates throughout the body and is typically used for symptoms such as hot flashes and night sweats. It may be taken as a pill or delivered through the skin using a patch, gel, or spray.Local vaginal estrogen is applied directly to vaginal tissues in low doses and is used primarily for genitourinary syndrome of menopause. It may help vaginal dryness, irritation, pain with sex, urinary urgency, and recurrent urinary tract infections in appropriate women. For more about the tissue changes that occur as estrogen declines, see Vaginal Atrophy.
Because local and systemic estrogen are used for different purposes and have different levels of systemic exposure, they should not be treated as interchangeable therapies.
| Treatment | Main Purpose | Common Forms | Can Help With |
|---|---|---|---|
| Systemic HRT | Treats broader menopause symptoms throughout the body | Pills, patches, gels, sprays | Hot flashes, night sweats, menopause-related sleep disruption, bone loss prevention |
| Local vaginal estrogen | Treats genitourinary symptoms directly in vaginal tissues | Creams, tablets/inserts, rings | Vaginal dryness, discomfort, pain with sex, some urinary symptoms, recurrent UTIs in appropriate women |
There is no single maximum duration of HRT that applies to every woman. Treatment length should be individualized based on symptoms, benefits, risks, age, and personal preferences.
For some women, symptoms improve enough that they choose to reduce or stop treatment after several years. Others continue longer when benefits remain meaningful and risks are acceptable.
Regular follow-up with a healthcare provider is important so the need for treatment, dose, route, and overall benefit-risk balance can be reassessed over time.
Hormone replacement therapy, or HRT, is used to replace hormones that decline during the menopause transition. Most treatments contain estrogen, with a progestogen added when needed for women who still have a uterus.
For many healthy women younger than 60 or within about 10 years of menopause onset, the benefit-risk balance of HRT is generally considered favorable when bothersome symptoms are present. Safety depends on individual medical history, the type and dose of hormones used, and the route of administration.
Yes. HRT may be used during perimenopause when symptoms such as hot flashes, night sweats, or sleep disruption become bothersome. Because pregnancy is still possible during perimenopause, HRT should not be relied on for contraception.
Systemic HRT is not considered a primary treatment for urinary incontinence. Local vaginal estrogen may help some urinary symptoms associated with genitourinary syndrome of menopause, such as urgency and recurrent urinary tract infections, but stress and urge incontinence usually require treatments directed at the specific bladder problem.
Systemic HRT circulates throughout the body and is generally used for symptoms such as hot flashes and night sweats. Local vaginal estrogen is applied directly to vaginal tissues in low doses and is primarily used for vaginal and urinary symptoms associated with menopause.
There is no single time limit that applies to every woman. Treatment duration should be individualized based on symptoms, benefits, risks, age, and personal preferences, with periodic review by a healthcare provider.
Women who still have a uterus generally need a progestogen along with systemic estrogen to help protect the uterine lining. Women who have had a hysterectomy may be able to use estrogen alone, depending on their medical history.
The Menopause Society. Hormone Therapy. Accessed August 2026.
American College of Obstetricians and Gynecologists. Hormone Therapy for Menopause. Accessed August 2026.
The Menopause Society. Genitourinary Syndrome of Menopause. Accessed August 2026.
National Health Service. Hormone Replacement Therapy (HRT). Accessed August 2026.
American Urological Association, Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction, and American Urogynecologic Society. Genitourinary Syndrome of Menopause Guideline. 2025.
Receive educational resources, exclusive offers, and new product information.
